Premature Rupture of Membrane Clinical Trial
Official title:
The Impact of Amniotic Fluid Index (AFI) on Maternal and Perinatal Outcomes in Pregnant Women With Preterm Premature Rupture of Membranes (PPROM)
Pregnant women who admitted with the complaint of amniotic fluid leakage between the
gestational ages of 23+0 and 33+0 and who finally were diagnosed as PPROM were included in
the study. Women with multiple gestations, cervical dilatation above 6 cm at the admission,
hypertensive diseases, cervical cerclage, fetal anomalies, olgohydramnios, polihydramnios,
and those who declined to involve in the study were excluded.
In all included women were examined at the admission for amniotic fluid index via trans
abdominal ultrasonography. AFI were measured by four quadrant technique, which is sum of the
deepest vertical length of pocket of fluid in each quadrant without any umbilical cord. All
included patients were assessed in two groups; women with AFI<5 and those with AFI≥5 cm.
Included patients were followed in terms of maternal and fetal complications. Maternal
complications were chorioamnionitis, placental abruption, placental retention, postpartum
endometritis, postpartum hemorrhage; while fetal complications comprised necessity of
admission to neonatal intensive care unit, neonatal sepsis, meconium aspiration syndrome,
respiratory distress syndrome, intraventricular hemorrhage, umbilical cord pH below 7.10,
APGAR score of 5th minute below 5. All complication rates were compared between the groups.
In addition, the time period between the diagnosis of PPROM and the time of delivery was
defined as latency period and were compared between the groups.
Pregnant women who admitted with the complaint of amniotic fluid leakage between the
gestational ages of 23+0 and 33+0 were examined for the inclusion criteria of the study.
Among them, women with usual history of gross amniotic fluid leakage as well as classical
speculum findings of ROM, such as pooling of amnitotic fluid within the posterior fornix or
vaginal wall, were diagnosed as PPROM and included in the study without any further
investigation. In case of the absence of these findings and suspected cases, PPROM was
diagnosed via placental alpha-microglobulin-1 test from the vaginal fluid. Those with
positive test results were included in the study. Women with multiple gestations, cervical
dilatation above 6 cm at the admission, hypertensive diseases, cervical cerclage, fetal
anomalies, olgohydramnios, polihydramnios, and those who declined to involve in the study
were excluded.
In all included women were examined at the admission for amniotic fluid index via trans
abdominal ultrasonography. AFI were measured by four quadrant technique, which is sum of the
deepest vertical length of pocket of fluid in each quadrant without any umbilical cord. All
included patients were assessed in two groups; women with AFI<5 and those with AFI≥5 cm.
Included patients were followed in terms of maternal and fetal complications. Maternal
complications were chorioamnionitis, placental abruption, placental retention, postpartum
endometritis, postpartum hemorrhage; while fetal complications comprised necessity of
admission to neonatal intensive care unit, neonatal sepsis, meconium aspiration syndrome,
respiratory distress syndrome, intraventricular hemorrhage, umbilical cord pH below 7.10,
APGAR score of 5th minute below 5. All complication rates were compared between the groups.
In addition, the time period between the diagnosis of PPROM and the time of delivery was
defined as latency period and were compared between the groups.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04478942 -
PROMMO Trial: Oral Misoprostol vs IV Oxytocin
|
Early Phase 1 | |
Recruiting |
NCT02819570 -
Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes
|
Phase 4 | |
Withdrawn |
NCT03172858 -
Randomized Control Trial of Intracervical Balloon Placement vs Oxytocin in Women With Term PROM and Unripe Cervices
|
N/A | |
Not yet recruiting |
NCT05134688 -
Magnesium Sulphate in Premature Rupture of Membranes
|
Early Phase 1 | |
Not yet recruiting |
NCT03689062 -
Premature Rupture of Membranes at 34 to 37 Weeks' Gestation
|
N/A | |
Recruiting |
NCT06273891 -
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
|
Phase 3 | |
Recruiting |
NCT04237142 -
Preterm Premature Rupture of Fetal Membranes: Cervical Ultrasound and Biological Markers to Diagnose Prematurity (RECHOBIOL)
|
N/A | |
Recruiting |
NCT04558996 -
Spanish Registry of Pregnant Women With COVID-19
|
||
Recruiting |
NCT04632017 -
Computerized Cardiotocography Monitoring of Fetuses With pPROM
|
||
Recruiting |
NCT03607929 -
HIDRATA Study: Efficacy of a Hydration Protocol in Nulliparous Women During Labor
|
N/A | |
Completed |
NCT03491826 -
Fetal and Maternal Outcome in Preterm Premature Rupture of Membranes (PPROM)
|
||
Enrolling by invitation |
NCT04451109 -
Dilapan-S®: A Multicenter US E-registry
|
||
Recruiting |
NCT04143685 -
Labor Induction With Misoprostol Versus Oxytocin in Women With Premature Rupture of Membranes
|
N/A | |
Completed |
NCT03251898 -
Correlation Between Premature Rupture of Membranes and Early-onset Neonatal Infections
|
||
Completed |
NCT03106311 -
The Use of Quantitative Pregnancy Test in Amniotic Fluid as a Diagnostic Tool for Rupture of Fetal Membranes
|
N/A |